指南与共识浆细胞疾病

英国血液学会指南:在血液科、心内科、神经内科、肾内科及全科诊所中早期诊断AL淀粉样变性

Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline.
指南 / 共识 · Br J Haematol · 2026-05-07

该指南由英国血液学会制定,旨在促进对系统性AL淀粉样变性的识别和怀疑。AL淀粉样变性由浆细胞克隆产生异常轻链并沉积于组织所致,生存取决于器官损伤程度,早期患者5年生存率约80%,晚期不足30%。指南强调该病可出现在任何诊所,包括普通内科/老年照护和全科诊所。

要点

  • AL淀粉样变性由浆细胞克隆产生异常轻链并沉积于组织所致。
  • 早期患者5年生存率约80%,晚期不足30%。
  • 该病可出现在任何诊所,需提高识别和怀疑。

核心结论

  • AL淀粉样变性生存取决于器官损伤程度,早期诊断有助于改善预后。

研究设计与样本

  • 英国血液学会制定的指南,旨在促进对AL淀粉样变性的识别和怀疑。

主要发现

  • 早期患者5年生存率约80%,晚期患者不足30%。

临床怎么用

  • 在血液科、心内科、神经内科、肾内科及全科诊所中提高对AL淀粉样变性的怀疑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AL amyloidosis is caused by a plasma cell clone that produces abnormal light chains that misfold and deposit as amyloid fibrils in tissues and thus affect organ function. The survival of patients with systemic amyloid light-chain (AL) amyloidosis largely depends on the extent of end-organ damage. Patients with early-stage disease can expect approximately 80% survival at 5 years with contemporary treatment, compared to less than 30% for those with advanced disease. The aim of this guideline is to facilitate recognition and raise suspicion of amyloidosis. It is important to recognise that amyloidosis can present in any clinic, including general medicine/care of the elderly and general practice.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Garg M, Choudhuri S, Parrish C, et al. Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline. Br J Haematol. 2026. PMID: 42099096. doi:10.1111/bjh.70472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。